WO2021169017A1 - Utilisation de cellules souches mésenchymateuses dans le traitement de la pneumonie à covid-19 sévère - Google Patents
Utilisation de cellules souches mésenchymateuses dans le traitement de la pneumonie à covid-19 sévère Download PDFInfo
- Publication number
- WO2021169017A1 WO2021169017A1 PCT/CN2020/086653 CN2020086653W WO2021169017A1 WO 2021169017 A1 WO2021169017 A1 WO 2021169017A1 CN 2020086653 W CN2020086653 W CN 2020086653W WO 2021169017 A1 WO2021169017 A1 WO 2021169017A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- stem cells
- mesenchymal stem
- ace2
- cells
- viral pneumonia
- Prior art date
Links
- 210000002901 mesenchymal stem cell Anatomy 0.000 title claims abstract description 69
- 206010035664 Pneumonia Diseases 0.000 title abstract description 8
- 208000025721 COVID-19 Diseases 0.000 title abstract description 4
- 241000700605 Viruses Species 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 14
- 241001678559 COVID-19 virus Species 0.000 claims description 13
- 206010035737 Pneumonia viral Diseases 0.000 claims description 13
- 208000009421 viral pneumonia Diseases 0.000 claims description 13
- 241000711573 Coronaviridae Species 0.000 claims description 12
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 claims description 6
- 239000003814 drug Substances 0.000 claims description 6
- 241000315672 SARS coronavirus Species 0.000 claims description 5
- 210000001185 bone marrow Anatomy 0.000 claims description 5
- 229940079593 drug Drugs 0.000 claims description 5
- 239000002609 medium Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- HJCMDXDYPOUFDY-WHFBIAKZSA-N Ala-Gln Chemical compound C[C@H](N)C(=O)N[C@H](C(O)=O)CCC(N)=O HJCMDXDYPOUFDY-WHFBIAKZSA-N 0.000 claims description 4
- 241000127282 Middle East respiratory syndrome-related coronavirus Species 0.000 claims description 4
- 230000000735 allogeneic effect Effects 0.000 claims description 4
- 229910002091 carbon monoxide Inorganic materials 0.000 claims description 4
- 210000004700 fetal blood Anatomy 0.000 claims description 4
- 210000003954 umbilical cord Anatomy 0.000 claims description 4
- 239000003242 anti bacterial agent Substances 0.000 claims description 3
- 229940088710 antibiotic agent Drugs 0.000 claims description 3
- 230000037396 body weight Effects 0.000 claims description 3
- 230000003169 placental effect Effects 0.000 claims description 3
- 210000004271 bone marrow stromal cell Anatomy 0.000 abstract description 17
- 108090000975 Angiotensin-converting enzyme 2 Proteins 0.000 abstract description 16
- 230000006870 function Effects 0.000 abstract description 6
- 206010052015 cytokine release syndrome Diseases 0.000 abstract description 4
- 210000002865 immune cell Anatomy 0.000 abstract description 4
- 206010050685 Cytokine storm Diseases 0.000 abstract description 2
- 210000004185 liver Anatomy 0.000 abstract description 2
- 102000053723 Angiotensin-converting enzyme 2 Human genes 0.000 abstract 2
- 230000002519 immonomodulatory effect Effects 0.000 abstract 1
- 238000010253 intravenous injection Methods 0.000 abstract 1
- 230000003908 liver function Effects 0.000 abstract 1
- 230000010016 myocardial function Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 32
- 102100035765 Angiotensin-converting enzyme 2 Human genes 0.000 description 14
- 238000000684 flow cytometry Methods 0.000 description 12
- 208000028399 Critical Illness Diseases 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 8
- 208000024891 symptom Diseases 0.000 description 7
- 238000002054 transplantation Methods 0.000 description 7
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 230000014509 gene expression Effects 0.000 description 6
- 238000004949 mass spectrometry Methods 0.000 description 6
- 229910052760 oxygen Inorganic materials 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 description 5
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 5
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 description 5
- 201000010099 disease Diseases 0.000 description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 5
- 210000002919 epithelial cell Anatomy 0.000 description 5
- 238000012163 sequencing technique Methods 0.000 description 5
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 4
- 206010037660 Pyrexia Diseases 0.000 description 4
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000012091 fetal bovine serum Substances 0.000 description 4
- 210000004072 lung Anatomy 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 238000011160 research Methods 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 108010074051 C-Reactive Protein Proteins 0.000 description 3
- 102100032752 C-reactive protein Human genes 0.000 description 3
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 102100037241 Endoglin Human genes 0.000 description 3
- 101000881679 Homo sapiens Endoglin Proteins 0.000 description 3
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000011324 bead Substances 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 239000010437 gem Substances 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 229910052751 metal Inorganic materials 0.000 description 3
- 239000002184 metal Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 208000013220 shortness of breath Diseases 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- 102100022464 5'-nucleotidase Human genes 0.000 description 2
- 102400000345 Angiotensin-2 Human genes 0.000 description 2
- 101800000733 Angiotensin-2 Proteins 0.000 description 2
- 102100028990 C-X-C chemokine receptor type 3 Human genes 0.000 description 2
- 102100032912 CD44 antigen Human genes 0.000 description 2
- 241000709687 Coxsackievirus Species 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 101100310856 Drosophila melanogaster spri gene Proteins 0.000 description 2
- 241001466953 Echovirus Species 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 101000678236 Homo sapiens 5'-nucleotidase Proteins 0.000 description 2
- 101000916050 Homo sapiens C-X-C chemokine receptor type 3 Proteins 0.000 description 2
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 description 2
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 2
- 241000725643 Respiratory syncytial virus Species 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 101150054399 ace2 gene Proteins 0.000 description 2
- 229950006323 angiotensin ii Drugs 0.000 description 2
- 239000003443 antiviral agent Substances 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 239000008367 deionised water Substances 0.000 description 2
- 229910021641 deionized water Inorganic materials 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 210000004379 membrane Anatomy 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 230000036387 respiratory rate Effects 0.000 description 2
- 210000002345 respiratory system Anatomy 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 238000001847 surface plasmon resonance imaging Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 230000014616 translation Effects 0.000 description 2
- 241000701161 unidentified adenovirus Species 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 102400000344 Angiotensin-1 Human genes 0.000 description 1
- 101800000734 Angiotensin-1 Proteins 0.000 description 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 description 1
- 102000004625 Aspartate Aminotransferases Human genes 0.000 description 1
- 108010003415 Aspartate Aminotransferases Proteins 0.000 description 1
- 206010003658 Atrial Fibrillation Diseases 0.000 description 1
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 description 1
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 description 1
- 102100028989 C-X-C chemokine receptor type 2 Human genes 0.000 description 1
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 208000003322 Coinfection Diseases 0.000 description 1
- 208000001528 Coronaviridae Infections Diseases 0.000 description 1
- 102000004420 Creatine Kinase Human genes 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 101150027068 DEGS1 gene Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015866 Extravasation Diseases 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 1
- 101001046686 Homo sapiens Integrin alpha-M Proteins 0.000 description 1
- 101000935043 Homo sapiens Integrin beta-1 Proteins 0.000 description 1
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 1
- 101001109426 Homo sapiens Nitric oxide-associated protein 1 Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 102100022338 Integrin alpha-M Human genes 0.000 description 1
- 102100022297 Integrin alpha-X Human genes 0.000 description 1
- 102100025304 Integrin beta-1 Human genes 0.000 description 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 description 1
- 208000007177 Left Ventricular Hypertrophy Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108020005196 Mitochondrial DNA Proteins 0.000 description 1
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 1
- 208000034486 Multi-organ failure Diseases 0.000 description 1
- 208000010718 Multiple Organ Failure Diseases 0.000 description 1
- 102100030856 Myoglobin Human genes 0.000 description 1
- 108010062374 Myoglobin Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010025020 Nerve Growth Factor Proteins 0.000 description 1
- 102100022495 Nitric oxide-associated protein 1 Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 206010053159 Organ failure Diseases 0.000 description 1
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 1
- 102100024616 Platelet endothelial cell adhesion molecule Human genes 0.000 description 1
- 229940096437 Protein S Drugs 0.000 description 1
- 238000003559 RNA-seq method Methods 0.000 description 1
- 238000011529 RT qPCR Methods 0.000 description 1
- 208000004756 Respiratory Insufficiency Diseases 0.000 description 1
- 206010038687 Respiratory distress Diseases 0.000 description 1
- 201000003176 Severe Acute Respiratory Syndrome Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 101710198474 Spike protein Proteins 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 102000018265 Virus Receptors Human genes 0.000 description 1
- 108010066342 Virus Receptors Proteins 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 208000038016 acute inflammation Diseases 0.000 description 1
- 230000006022 acute inflammation Effects 0.000 description 1
- 206010069351 acute lung injury Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000002821 alveolar epithelial cell Anatomy 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 208000013404 behavioral symptom Diseases 0.000 description 1
- 210000003123 bronchiole Anatomy 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000037029 cross reaction Effects 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 238000013480 data collection Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000001900 endoderm Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000036251 extravasation Effects 0.000 description 1
- 230000001434 glomerular Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000008975 immunomodulatory function Effects 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 231100000516 lung damage Toxicity 0.000 description 1
- 210000001165 lymph node Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 238000005399 mechanical ventilation Methods 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 208000029744 multiple organ dysfunction syndrome Diseases 0.000 description 1
- 230000003680 myocardial damage Effects 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 210000002826 placenta Anatomy 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000513 principal component analysis Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 210000004777 protein coat Anatomy 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000029865 regulation of blood pressure Effects 0.000 description 1
- 230000036454 renin-angiotensin system Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 201000004193 respiratory failure Diseases 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 231100000279 safety data Toxicity 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 238000012174 single-cell RNA sequencing Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 108010058734 transglutaminase 1 Proteins 0.000 description 1
- 238000013519 translation Methods 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 229960001322 trypsin Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
Definitions
- the present disclosure belongs to the field of biomedical technology, and relates to a method for treating severe or critical COVID19 pneumonia by using ACE2-negative mesenchymal stem cells.
- ACE2 is a type I glycoprotein on the cell membrane. It has two major functional domains, namely the extracellular and transmembrane domains containing carboxypeptidase functions. Although ACE2 and ACE1 share 61% homology, their physiological function is to remove the C-terminal amino acid residues of angiotensin II (AngII) to become inactive angiotensin 1. Because the renin-angiotensin system (RAS) is related to blood pressure regulation, there are many studies in cardiovascular diseases. It has been found that ACE2 gene polypeptide is associated with hypertension, left ventricular hypertrophy, and atrial fibrillation.
- AngII angiotensin II
- RAS renin-angiotensin system
- Viruses are completely parasitic organisms and must enter the host cell through the receptor to survive and multiply.
- SARS virus receptor the research work of many research groups around the world has confirmed that the first step for 2019-nCoV to invade host cells is to specifically bind to the ACE2 receptor on the human cell surface through the virus surface spike.
- ACE2 receptors such as type II lung epithelial cells and small intestinal epithelium.
- 2019-nCoV invades the cells of the corresponding part, it will cause the corresponding organ dysfunction and even failure.
- the most important damaged organ is the lung.
- 2019-nCoV The sense single-stranded RNA virus 2019-nCoV is transmitted from certain animals or patients to humans through droplets and close contact.
- 2019-nCoV uses ACE2 on type II lung epithelial cells as the receptor, and the viral spike protein binds to it, and the virus is endocytosed into the cell. With the help of cathepsin in the lysosome, the protein coat of the virus is digested. 2019-nCoV "hijacks" the host cell's protein translation system.
- direct translation includes the proteins required by the virus to replicate genome enzymes and structures such as envelopes and spines, and then assemble them into new virus particles.
- a replication (life) cycle of the virus (6 steps: enter the human body to adhere, penetrate the membrane, unshell, replicate, assemble, and release).
- a large number of viruses destroy epithelial cells and release viruses, thereby infecting more cells. Damaged epithelial cells can release contents, causing acute inflammation such as inflammatory cell extravasation, and severe cases can cause cytokine release syndrome. It then leads to acute lung injury and damage to various organs in the body, causing multiple organ failure, which seriously threatens people's lives.
- the new coronavirus disease (COVID-19) caused by the coronavirus 2019-nCoV has had a huge negative social impact and poses a huge threat to global public health.
- the severity of COVID-19 pneumonia can be divided into four levels: light, normal, severe, and critical.
- cytokine storms cause severe acute respiratory syndrome and many other serious complications. Preventing and reversing the cytokine storm may be the key to rescuing critically ill patients.
- MSCs Mesenchymal stem cells
- a mesenchymal stem cell is provided.
- an ACE2-negative mesenchymal stem cell is provided.
- a negative ACE2 (ACE2 also as -) refers to the use of the prior art known means for detecting ACE2 in mesenchymal stem cells or cell surface without detectable levels of ACE2.
- the mesenchymal stem cells are derived from: fat, umbilical cord blood, umbilical cord, bone marrow, placenta. In other embodiments, the mesenchymal stem cells are autologous mesenchymal stem cells, or allogeneic mesenchymal stem cells.
- ACE2-negative mesenchymal stem cells are obtained through the following culture conditions:
- a temperature of 30°C to 40°C such as 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40°C, and the range between any two values (may not be an integer value);
- 4% to 6% CO 2 e.g. 4.1, 4.2, 4.3, 4.4, 4.5, 4.6, 4.7, 4.8, 4.9, 5.0, 5.1, 5.2, 5.3, 5.4, 5.5, 5.6, 5.7, 5.8, 5.9, 6.0%
- mesenchymal stem cells are cultured in DMEM/F12 medium for 2 to 20 generations (for example, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10).
- the DMEM/F12 medium is supplemented with any one or a combination selected from the following:
- w/v 0.1% to 30% w/v, such as 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25% w/v FBS,
- 1% to 3% w/v such as 1, 1.5, 2, 2.5, 3% w/v antibiotics (e.g. penicillin/streptomycin), and
- 0.1 mM to 30 mM such as 0.1, 0.5, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 15, 20, 25 mM GlutaMAX TM -I.
- the use of the aforementioned ACE2-negative mesenchymal stem cells for the treatment of viral pneumonia is also provided.
- the use of the aforementioned ACE2-negative mesenchymal stem cells in the preparation of drugs for the treatment of viral pneumonia is also provided.
- the ACE2-negative mesenchymal stem cells of the present application are particularly effective against severe viral pneumonia.
- the virus is selected from: rhinovirus, coronavirus, adenovirus, influenza virus, parainfluenza virus, respiratory syncytial virus, Echo virus, Coxsackie virus.
- the coronavirus is selected from: SARS-CoV, MERS-CoV, and 2019-nCoV.
- a method for treating viral pneumonia including the steps of: administering a therapeutically effective amount of ACE2-negative mesenchymal stem cells to the patient.
- the patient refers to a virus carrier, especially a patient who has or may have symptoms due to the presence of the virus.
- a virus carrier especially a patient who has or may have symptoms due to the presence of the virus.
- patients are especially severe or critically ill patients.
- the virus is selected from: rhinovirus, coronavirus (may mention SARS-CoV, MERS-CoV, 2019-nCoV), adenovirus, influenza virus, parainfluenza virus, respiratory syncytial virus, Echo virus, Coxsackie Virus.
- the mesenchymal stem cells are selected from: adipose mesenchymal stem cells, cord blood mesenchymal stem cells, umbilical cord mesenchymal stem cells, bone marrow mesenchymal stem cells, placental mesenchymal stem cells.
- the mesenchymal stem cells are autologous mesenchymal stem cells, or allogeneic mesenchymal stem cells.
- therapeutically effective amount refers to the amount of the drug, compound, or pharmaceutical composition necessary to obtain any one or more beneficial or desired therapeutic results .
- beneficial or desired results include: improving clinical results (eg, reducing morbidity, mortality, improving one or more symptoms), reducing the severity, delaying the onset of the disease (including the disease or its complications, in the development process of the disease) Intermediate pathological phenotypes, biochemical, histological and/or behavioral symptoms presented in ).
- Figure 1 CT image of a severely ill patient with COVID-19 (cell transplantation performed on January 31).
- Figure 2A to Figure 2C Mass spectrometry flow cytometry of peripheral blood mononuclear cells in critically ill patients.
- Figure 3A to Figure 3N RNA sequence analysis.
- ACE2 (Figure 3A), TMPRSS2 (Figure 3B), TGF- ⁇ (Figure 3C), HGF (Figure 3D), LIF (Figure 3E), GAL (Figure 3F), NOA1 (Figure 3G), FGF (Figure 3H), VEGF (Figure 3I), EGF (Figure 3J), BDNF (Figure 3K), NGF ( Figure 3L), SPA ( Figure 3M) and SPC ( Figure 3N).
- a dot represents a cell, and dark and light colors represent high expression and low expression, respectively.
- Figure 4A to Figure 4F Using flow cytometry to identify the expression of MSCs cell surface markers.
- Figures 5A and 5B high-throughput single-cell sequencing of cell gene numbers (Figure 5A) and characteristic maps of UMIs ( Figure 5B).
- FIG. 6A to Figure 6D 10 ⁇ -scRNA sequence analysis MSCs marker gene expression: CD105 ( Figure 6A), CD90 ( Figure 6B), CD73 ( Figure 6C) and CD45 ( Figure 6D).
- FIG. 7A and Figure 7B ACE2 gene is not expressed in MSCs (Figure 7A); only one ACE2 + MSC and the remaining 12499 ACE2 - MSCs are differentially expressed in the first 60 genes ( Figure 7B).
- Figure 8A and Figure 8B TMPRSS2 gene expression (Figure 8A); and differentially expressed genes between TMPRSS2 + MSC and TMPRSS2 - MSC ( Figure 8B).
- Figures 9A to 9C High-throughput single-cell sequencing technology revealed that MSCs highly expressed genes differentiated in the endoderm direction (Figure 9A), and highly expressed SPA (Figure 9B) and SPC (Figure 9C).
- Figure 10A to Figure 10D Serum cytokine IL-10 (Figure 10A), growth factor VEGF ( Figure 10B), chemokine IP-10 (Figure 10C) and tumor necrosis factor TNF- ⁇ ( Figure 10D) before and after MSCs treatment Proportion.
- Figures 11A to 11C Flow cytometry results of peripheral blood mononuclear cells.
- RNA real-time reverse transcription polymerase chain reaction RT-PCR
- the RT-PCR test is carried out at the Chinese Center for Disease Control and Prevention.
- the sequence used to target the membrane gene of the coronavirus (Lancet, 2020Feb 15,395-10223: 497-506) is as follows:
- the expansion conditions are: 50°C for 15 minutes, 95°C for 3 minutes, 45 cycles, each cycle includes 95°C for 15 seconds and 60°C for 30 seconds.
- the oxygen saturation is ⁇ 93%
- ICU monitoring and treatment is required.
- DMEM/F12 fetal bovine serum (FBS), transglutaminase-I, trypsin, penicillin and streptomycin were all purchased from Gibco (California, USA). All other reagents are of analytical grade and do not require further purification.
- the adipose-derived mesenchymal stem cells were cultured in DMEM/F12 medium (supplemented with 10% FBS, 1% penicillin/streptomycin and 2mM GlutaMAX TM -I) under 4% to 6% CO 2 at 30 to 40°C for 2 generations To the 10th generation.
- the surface phenotypes CD29, CD44, CD105, CD73, and CD90 were positive by flow cytometry; CD31, CD34, and CD45.
- the sequencing library is constructed.
- the library was constructed using a chromium controller (10x Genomics, Pleasanton, California).
- GemCode technology is used to encapsulate single cells containing barcode oligonucleotides, reagents and gel beads into nanoliter GEMs (latex gel beads).
- GEMs latex gel beads
- single cell polyadenylation mRNA cleavage and barcode reverse transcription are performed. Clean up the GEMs after RT and amplify cDNA. Fragment the cDNA, repair the ends of the fragments, and add A-tailing to the 3'end.
- the adapter Connect the adapter to the segment with the double-sided SPRI selected. After sample exponential PCR, another two-way SPRI selection is performed. The quality control library was sorted. The final library is quantified in two ways: using the Agilent 2100 bioanalyzer to determine the average molecular length, and using real-time quantitative PCR to quantify the library.
- the inventors performed high-throughput single-cell RNA sequencing (10 ⁇ RNA-seq) to accurately detect the full gene expression profile of MSCs, especially the ACE2 and TMPRSS2 genes, as well as the secretion factors, nutritional factors, and alveolar epithelial cells II ( AT-2) Genes related to differentiation.
- MSCs were suspended in 100ml of normal saline, and the total number of transplanted cells was calculated at 1 ⁇ 10 6 cells per kilogram of body weight.
- the window period of cell transplantation refers to the time during which the symptoms or/and signs are still getting worse while the expected treatment is being performed. The injection takes about 40 minutes and the speed is about 40 drops per minute.
- -Secondary efficacy indicators mainly include: total lymphocyte count and subpopulations, chest CT, respiratory rate and patient symptoms (especially fever and shortness of breath);
- the treatment measures ie antiviral drugs and respiratory support
- results are also recorded.
- PBMC samples were collected from COVID-19 patients who received MSCs transplantation, and PBMC from healthy donors were used as a control group.
- CD45 antibodies Three samples from healthy donors, patients at the beginning, and patients on the 6th day after treatment were stained with CD45 antibodies. These antibodies were labeled with different metal tags (such as 89, 141, and 172) to minimize the number of samples. Internal cross-reactions between.
- the antibody was combined with MaxPar ⁇ 8 polymer kit (Fluidigm). All metal-bound antibodies are titrated to the optimal concentration before use.
- the cells were counted, diluted to 1 ⁇ 10 6 cells/ml in PBS, and permeated with 80% methanol at 0°C for 15 min. Washed 3 times in CSB, incubated with 50 ⁇ L CSD antibody at RT for 30 min, washed three times in CSB, and incubated overnight in fix-perm buffer (Fluidigm) with 0.125 ⁇ m intercalant at 4°C.
- the cells were intercalated and cultured, they were washed 3 times with frozen PBS and 3 times with deionized water. Before collection, the sample was resuspended in deionized water containing 10% EQ 4 element beads (Fluidigm), and the cell concentration was adjusted to 1 ⁇ 10 6 cells/ml. Data collection was performed on a Helios mass cytometer (Fluidigm). The original FCS data was normalized, and everyone’s .fcs files were collected.
- the inventors performed MSCs transplantation experiments on 7 COVID-19 patients from Beijing You'an Hospital to explore the safety and effectiveness of the cell therapy.
- the inventor also performed MSCs vein transplantation on patients. Observe for 14 days after cell injection.
- the main safety consideration is toxic effects, including infusion or allergic reactions.
- the main therapeutic effect is the immunomodulatory function of the infused mesenchymal stem cells, combined with plasma C-reactive protein levels and blood oxygen saturation.
- the secondary efficacy indicators mainly include the total number and subpopulations of lymphocytes determined by mass spectrometry flow cytometry, chest CT, respiratory rate, and patient symptoms (especially fever and shortness of breath).
- the clinical manifestations such as fever and shortness of breath generally alleviate or disappear within 2 to 4 days, and the blood oxygen saturation can reach more than 95%; laboratory examination indicators C-reactive protein can be significantly reduced within 7-10 days, chest CT shows ground glass-like changes in the lungs, which are significantly relieved in about 7 days (Figure 1); peripheral blood immune cell subsets can be reversed to pre-infection levels (Figure 2A to Figure 2C) ).
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Wood Science & Technology (AREA)
- Immunology (AREA)
- Developmental Biology & Embryology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- General Engineering & Computer Science (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
L'invention concerne l'utilisation de cellules souches mésenchymateuses dans le traitement de la pneumonie à COVID-19 sévère. L'invention concerne des MSC ACE2 négatives, et se caractérise en ce qu'elle est sûre et efficace pour administrer les MSC à un patient souffrant de COVID-19, en particulier un patient gravement atteint, par injection intraveineuse. Les MSC ACE2 négatives peuvent jouer un rôle positif grâce à des effets immunomodulateurs directs sur une tempête de cytokines et des cellules immunitaires, protégeant ainsi les fonctions du foie et les fonctions myocardiques.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202080079752.5A CN114829583A (zh) | 2020-02-25 | 2020-04-24 | 间充质干细胞在治疗重症covid19肺炎中的用途 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010116232.9 | 2020-02-25 | ||
CN202010116232 | 2020-02-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2021169017A1 true WO2021169017A1 (fr) | 2021-09-02 |
Family
ID=77490386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2020/086653 WO2021169017A1 (fr) | 2020-02-25 | 2020-04-24 | Utilisation de cellules souches mésenchymateuses dans le traitement de la pneumonie à covid-19 sévère |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN114829583A (fr) |
WO (1) | WO2021169017A1 (fr) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210308190A1 (en) * | 2020-04-07 | 2021-10-07 | Miguelangelo J. Perez-Cruet | Human umbilical cord blood mesenchymal stem cell transfusion immunotherapy for treatment of cytokine storm associated with coronavirus infection |
WO2023063739A1 (fr) * | 2021-10-14 | 2023-04-20 | 재단법인대구경북과학기술원 | Vésicules extracellulaires dérivées de cellules souches mésenchymateuses et auxquelles l'ace2 est fixée, et leur utilisation |
WO2024041292A1 (fr) * | 2022-08-22 | 2024-02-29 | 中国药科大学 | Utilisation de cellules souches mésenchymateuses de cordon ombilical dans la prévention de maladies pulmonaires provoquées par une infection virale |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013082543A1 (fr) * | 2011-11-30 | 2013-06-06 | Advanced Cell Technology, Inc. | Cellules stromales mésenchymateuses et utilisation s'y rapportant |
WO2019200030A1 (fr) * | 2018-04-13 | 2019-10-17 | Incyte Corporation | Biomarqueurs pour une maladie du greffon contre l'hôte |
CN110418645A (zh) * | 2017-03-08 | 2019-11-05 | 日本乐敦制药株式会社 | 含有ror1阳性的间充质干细胞的、用于预防或处置伴随纤维化的疾病的药物组合物、及其制备方法、以及使用ror1阳性的间充质干细胞的伴随纤维化的疾病的预防或处置方法 |
WO2019231266A1 (fr) * | 2018-05-30 | 2019-12-05 | 주식회사 강스템바이오텍 | Cellule souche mésenchymateuse dérivée d'une cellule souche pluripotente induite humaine à gène hla supprimé et son procédé de préparation |
CN110777113A (zh) * | 2019-09-10 | 2020-02-11 | 中山大学 | 一种用于日本血吸虫感染治疗的间质干细胞处理方法 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101480410B (zh) * | 2009-02-18 | 2011-05-11 | 南京大学医学院附属鼓楼医院 | 脐带间质干细胞在制备治疗自身免疫性疾病药物中的应用 |
KR101971323B1 (ko) * | 2016-10-17 | 2019-04-23 | 사회복지법인 삼성생명공익재단 | 면역질환 치료를 위한 고효능 줄기세포 선별방법 |
CN110548048B (zh) * | 2019-10-14 | 2023-05-02 | 广州熙帝生物科技有限公司 | 造血干细胞用于制备治疗病毒性疾病的制剂的应用 |
-
2020
- 2020-04-24 WO PCT/CN2020/086653 patent/WO2021169017A1/fr active Application Filing
- 2020-04-24 CN CN202080079752.5A patent/CN114829583A/zh active Pending
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2013082543A1 (fr) * | 2011-11-30 | 2013-06-06 | Advanced Cell Technology, Inc. | Cellules stromales mésenchymateuses et utilisation s'y rapportant |
CN110418645A (zh) * | 2017-03-08 | 2019-11-05 | 日本乐敦制药株式会社 | 含有ror1阳性的间充质干细胞的、用于预防或处置伴随纤维化的疾病的药物组合物、及其制备方法、以及使用ror1阳性的间充质干细胞的伴随纤维化的疾病的预防或处置方法 |
WO2019200030A1 (fr) * | 2018-04-13 | 2019-10-17 | Incyte Corporation | Biomarqueurs pour une maladie du greffon contre l'hôte |
WO2019231266A1 (fr) * | 2018-05-30 | 2019-12-05 | 주식회사 강스템바이오텍 | Cellule souche mésenchymateuse dérivée d'une cellule souche pluripotente induite humaine à gène hla supprimé et son procédé de préparation |
CN110777113A (zh) * | 2019-09-10 | 2020-02-11 | 中山大学 | 一种用于日本血吸虫感染治疗的间质干细胞处理方法 |
Non-Patent Citations (3)
Title |
---|
LENG, Z.K. ET AL.: "Transplantation of ACE2-Mesenchymal Stem Cells Improves the Outcome of Patients with COVID-19 Pneumonia", AGING AND DISEASE, vol. 11, no. 2, 30 April 2020 (2020-04-30), XP055742483, DOI: 10.14336/AD.2020.0228 * |
LIU GUANGYANG, LIBO ZHENG, HAO WANG, YAFANG XIE, LI MIAO, KELING CHENG, YONGJUN LIU: "Therapy of novel coronavirus pneumonia with mesenchymal stem cells", YAOWU PINGJIA YANJIU [=DRUG EVALUATION RESEARCH], YAOWU PINGJIA YANJIU ZAZHI BIANJIBU, CN, vol. 43, no. 3, 18 February 2020 (2020-02-18), CN, pages 372 - 377, XP055840547, ISSN: 1674-6376, DOI: 10.7501/j.issn.1674-6376.2020.03.002 * |
METCALFE SU M: "Mesenchymal stem cells and management of COVID-19 pneumonia", MEDICINE IN DRUG DISCOVERY, ELSEVIER B.V, NETHERLANDS, 19 March 2020 (2020-03-19), Netherlands, pages 100019 - 100019, XP055840549, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7147223/pdf/main.pdf> DOI: 10.1016/j.medidd.2020.100019 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210308190A1 (en) * | 2020-04-07 | 2021-10-07 | Miguelangelo J. Perez-Cruet | Human umbilical cord blood mesenchymal stem cell transfusion immunotherapy for treatment of cytokine storm associated with coronavirus infection |
WO2023063739A1 (fr) * | 2021-10-14 | 2023-04-20 | 재단법인대구경북과학기술원 | Vésicules extracellulaires dérivées de cellules souches mésenchymateuses et auxquelles l'ace2 est fixée, et leur utilisation |
WO2024041292A1 (fr) * | 2022-08-22 | 2024-02-29 | 中国药科大学 | Utilisation de cellules souches mésenchymateuses de cordon ombilical dans la prévention de maladies pulmonaires provoquées par une infection virale |
Also Published As
Publication number | Publication date |
---|---|
CN114829583A (zh) | 2022-07-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021169017A1 (fr) | Utilisation de cellules souches mésenchymateuses dans le traitement de la pneumonie à covid-19 sévère | |
US10729727B2 (en) | Mesenchymal stem cells and uses therefor | |
Grote et al. | The angiogenic factor CCN1 promotes adhesion and migration of circulating CD34+ progenitor cells: potential role in angiogenesis and endothelial regeneration | |
JP5961220B2 (ja) | 間充織幹細胞とその使用 | |
Jamshidi et al. | Proposed mechanisms of targeting COVID-19 by delivering mesenchymal stem cells and their exosomes to damaged organs | |
Yadav et al. | Mesenchymal stem cell immunomodulation and regeneration therapeutics as an ameliorative approach for COVID-19 pandemics | |
TW201130977A (en) | Mesenchymal stem cells (MSCs) isolated from mobilized peripheral blood | |
Yip et al. | Neural stem cells as novel cancer therapeutic vehicles | |
WO2007142651A1 (fr) | Procédés et compositions pour le traitement de la neuropathie | |
US20210093713A1 (en) | Activation of resident memory t cells for the treatment of cancer | |
Peltzer et al. | Interferon-γ and hypoxia priming have limited effect on the miRNA landscape of human mesenchymal stromal cells-derived extracellular vesicles | |
Kawai et al. | IL-33 drives the production of mouse regulatory T cells with enhanced in vivo suppressive activity in skin transplantation | |
Salahuddin et al. | Processing of bronchoalveolar lavage fluid and matched blood for alveolar macrophage and CD4+ T-cell immunophenotyping and HIV reservoir assessment | |
Yang et al. | Adiponectin promotes endothelial cell differentiation from human peripheral CD14+ monocytes in vitro | |
WO2014089397A1 (fr) | Compositions et méthodes de traitement et de prévention de la fibrose pulmonaire | |
Cabezas et al. | In vitro preconditioning of equine adipose mesenchymal stem cells with prostaglandin E2, substance P and their combination changes the cellular protein secretomics and improves their immunomodulatory competence without compromising stemness | |
Sakinah et al. | Stem cell therapy in dengue virus-infected BALB/C mice improves hepatic injury | |
JP2018519805A (ja) | 組換え腫瘍溶解性ウイルスおよびその使用 | |
Ismael et al. | Matrix Metalloproteinase-3 and Tissue inhibitor of metalloproteinase-2 as Diagnostic Markers for COVID-19 Infection | |
Mahmoudi et al. | Human bone marrow mesenchymal stromal cells attenuate tissue injury and reduce inflammation in experimental acute pancreatitis | |
CN112057474A (zh) | 间充质干细胞用于调控病毒性感染患者单核细胞的应用 | |
BRPI0717150B1 (pt) | Usos de células-tronco mesenquimais | |
Niethamer et al. | A longitudinal atlas of post-viral lung regeneration reveals persistent injury-associated cell states | |
Mendiratta et al. | Synergistic Hypoxia and Apoptosis Conditioning Unleashes Superior Mesenchymal Stem Cells Efficacy in Acute Graft-versus-Host-Disease | |
Zanaty et al. | Variations in levels of ACE2 and TMPRSS2 receptors among COVID-19 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 20922079 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 20922079 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 19/09/2023) |